Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2025-03-28 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于召开2024年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed and voted on, shareholder registration, and proxy voting instructions. It references the 2024 Annual Report and other related reports as agenda items but does not contain the reports themselves. The document is a formal notification to shareholders about the AGM and how to participate, which fits the definition of AGM Information (AGM-R). The document length is over 5,000 characters and contains detailed meeting logistics and agenda, confirming it is not a brief announcement or a report publication announcement. Therefore, the correct classification is AGM Information (AGM-R).
2025-03-28 Chinese
2024年度独立董事述职报告（朱厚佳）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Shenzhen Salubris Pharmaceuticals Co., Ltd. for the year 2024. It includes the director's background, independence confirmation, attendance at board and committee meetings, oversight activities, communication with internal audit and accounting firms, and evaluation of company governance and financial reporting. The content focuses on the director's duties and activities related to corporate governance and audit oversight rather than presenting financial statements or audit opinions themselves. This type of document is typically classified as Board/Management Information (MANG) because it reports on board-level activities and management oversight rather than being a full annual report, audit report, or other financial filing. The document length (6993 characters) and detailed narrative support this classification rather than a brief announcement or a full financial report. Therefore, the appropriate classification is MANG with high confidence.
2025-03-28 Chinese
2024年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by Shenzhen Salubris Pharmaceuticals Co., Ltd. for the year 2024. It includes specifics on the amount of funds raised, their allocation, usage, investment projects, changes in project implementation, cash management of idle funds, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2024. This type of report is typically a specialized disclosure related to capital raising and fund usage, which aligns with the category of Capital/Financing Update (CAP). It is not an annual report, earnings release, or other types of filings. The document length and content confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-03-28 Chinese
董事会对独立董事独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors. It references relevant laws and regulations about independent directors and confirms their independence status. This type of document is related to governance and board oversight rather than financial results, audit, or shareholder voting. It is not an announcement of a meeting or voting results, nor is it a financial report or earnings release. The content fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is short but contains substantive governance content, not just an announcement or certification. Therefore, the classification is CGR with high confidence.
2025-03-28 Chinese
2024年度独立董事述职报告（王学恭）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report". It is a detailed report by an independent director about their duties, attendance, and activities during the year 2024. The content includes personal background, attendance at board meetings, participation in committees, communication with shareholders, supervision of company governance, and other duties performed. It is a formal report on the independent director's work and responsibilities for the year, not an announcement or a brief summary. This type of document fits best under the category of Board/Management Information (MANG), as it relates to the activities and reports of a member of the board of directors. It is not an annual report, audit report, or any other financial or regulatory filing. The length and detail confirm it is a full report, not a short announcement or certification. Therefore, the classification is MANG with high confidence.
2025-03-28 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Audit Report" and includes detailed audit opinions on the effectiveness of the company's internal control over financial reporting as of December 31, 2024. It is issued by a certified public accounting firm and includes an internal control self-evaluation report by the company. The content focuses on the audit of internal controls, the responsibilities of the company and auditors, the scope and standards of the internal control evaluation, and the conclusions regarding the effectiveness of internal controls. There are no financial statements or comprehensive annual financial performance data typical of an Annual Report (10-K) or Interim Report (IR). The document is a standalone audit report on internal controls, which fits the definition of an Audit Report / Information (AR). The document length is about 4850 characters, which is sufficient to be the report itself rather than a mere announcement. Therefore, the correct classification is AR with high confidence. FY 2024
2025-03-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.